ARO-APOC3
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 32/100
32
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Dyslipidemias
Conditions
Dyslipidemias
Trial Timeline
Jul 7, 2022 → Sep 18, 2025
NCT ID
NCT05413135About ARO-APOC3
ARO-APOC3 is a phase 2 stage product being developed by Arrowhead Pharmaceuticals for Dyslipidemias. The current trial status is completed. This product is registered under clinical trial identifier NCT05413135. Target conditions include Dyslipidemias.
What happened to similar drugs?
6 of 6 similar drugs in Dyslipidemias were approved
Approved (6) Terminated (0) Active (0)
Hype Score Breakdown
Clinical
12
Activity
8
Company
12
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05413135 | Phase 2 | Completed |
Competing Products
15 competing products in Dyslipidemias
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| LY3202328 + Placebo + Atorvastatin + Simvastatin | Eli Lilly | Phase 1 | 29 |
| Rosuampin 10/5mg + Rosuampin 20/5mg + Amlodipine/Atorvastatin 5/20mg | Yuhan | Approved | 43 |
| LY3475766 - IV + LY3475766 - SC + Placebo - IV + Placebo - SC | Eli Lilly | Phase 1 | 29 |
| LY3885125 + Placebo | Eli Lilly | Phase 1 | 21 |
| LY3561774 + Placebo | Eli Lilly | Phase 1 | 29 |
| LY3561774 + Placebo | Eli Lilly | Phase 2 | 35 |
| LY2484595 + Placebo + Atorvastatin | Eli Lilly | Phase 2 | 35 |
| Atorvastatin + Atorvastatin | Pfizer | Approved | 43 |
| Atorvastatin | Pfizer | Approved | 43 |
| Atorvastatin + Atorvastatin + Atorvastatin | Pfizer | Approved | 43 |
| Vupanorsen + Placebo | Pfizer | Phase 2 | 35 |
| Atorvastatin | Pfizer | Approved | 43 |
| Atorvastatin + Atorvastatin + Atorvastatin | Pfizer | Approved | 43 |
| GWP42003 + GWP42003 + GWP42004 + Placebo | Jazz Pharmaceuticals | Phase 2 | 32 |
| ARO-ANG3 + sterile normal saline (0.9% NaCl) | Arrowhead Pharmaceuticals | Phase 1 | 26 |